INBSNasdaqSurgical & Medical Instruments & ApparatusUS GAAP · USD

Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc. develops and sells the Intelligent Fingerprinting Platform, a non-invasive drug screening system that uses fingerprint sweat, disposable cartridges, and a handheld reader to detect drugs of abuse. The company is commercializing this platform in markets outside the United States and is expanding through distributors and strategic partnerships across the UK, Europe, and APAC.

Kysy yhtiöstä
Liikevaihto4,2milj. USD
+38,1 %v/v
Liikevoitto (EBIT)−12,6milj. USD
−18,1 %v/v
EBIT-marginaali−299,1%
+50,7 %-yks.v/v
Nettotulos−12,4milj. USD
−17,6 %v/v
Vapaa kassavirta−12,1milj. USD
−21,6 %v/v

Tilikausi 2026 · muutos edellisvuodesta

Kehitys 2021–2026

−15−10−505milj. USD2021: 2,0 milj. USD2021: EBIT −5,6 milj. USD20212022: EBIT −8,3 milj. USD20222023: 1,3 milj. USD2023: EBIT −13 milj. USD20232024: 3,1 milj. USD2024: EBIT −10 milj. USD20242025: 3,1 milj. USD2025: EBIT −11 milj. USD20252026: 4,2 milj. USD2026: EBIT −13 milj. USD20264,2−13
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Intelligent Bio Solutions Inc

Liiketoiminta

Osuus liikevaihdosta
Cartridges58 %

Disposable fingerprint sweat cartridges used for drug screening and recurring consumable revenue.

Readers27 %

Portable handheld analysis units that read cartridge results and enable the screening workflow.

Accessories and other sales15 %

Ancillary products and accessories sold alongside the core screening system.

Tuotteet

Raportoitu · osuus liikevaihdosta
59,0%21,4%19,6%FY2026100 %
  • Sales of Goods Cartidges59,0 %
  • Sales of Goods Readers21,4 %
  • Other Sales Accessories19,6 %

Lähde: 10-K FY2026, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Customers are safety-critical organizations that need rapid, non-invasive drug screening for workforce, compliance, or treatment purposes. The company also serves judicial and rehabilitation-related users that need portable testing with fast turnaround and lower sample-handling burden than traditional methods.

Safety-critical employers

Construction, transportation, logistics, manufacturing, and engineering customers buy the system to screen workers quickly and non-invasively.

Drug treatment and rehabilitation providers

Treatment organizations use the platform for rapid screening in rehabilitation settings where ease of use and patient acceptance matter.

Judicial and public-sector users

Courts and related organizations buy portable testing tools for enforcement and monitoring use cases.

Distribution partners

Local distributors and diagnostic partners buy and resell the platform in their territories to expand market reach.

Strategia

The company is focused on shifting revenue toward higher-margin cartridges while maintaining the installed base of readers that enables recurring consumable sales. It is also expanding geographic reach through distributors and partnerships, while investing in regulatory approvals, product upgrades, and intellectual property to support broader commercialization.

Grow cartridge-led recurring revenueLyhyt aikaväli

Cartridges carry materially higher contribution margin than readers and support repeat purchases.

Expand European distributionKeskipitkä aikaväli

Europe is the company’s most developed commercial region and a key source of near-term growth.

Enter APAC marketsKeskipitkä aikaväli

Australia, New Zealand, and broader APAC offer additional addressable markets but require regulatory readiness.

Strengthen product and IP positionKeskipitkä aikaväli

Product upgrades and patents help support adoption, localization, and competitive differentiation.

Maantiede

Q1/2026

The company is headquartered in New York but operates through subsidiaries in Delaware, Australia, and the UK, reflecting a cross-border commercialization model. Management is prioritizing growth in the United Kingdom and mainland Europe while building sales and regulatory infrastructure for Australia, New Zealand, and broader APAC markets. Recent disclosures also show active expansion into Spain, Andorra, and other European and Middle Eastern markets through partners.

UK99 %
Americas0,4 %
Asia Pacific0,4 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

The business remains exposed to customer concentration, supplier concentration, and execution risk as it scales a specialized medical technology platform. It also faces regulatory, funding, and listing-related risks typical of early commercial medtech companies, including dependence on approvals, government support, and continued access to capital.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Customer concentration1Regulatory approval risk2Financing and going-concern pressure3Supplier concentration4Nasdaq listing compliance5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Customer concentrationVaikutus: KorkeaTodennäköisyys: Korkea

    A small number of customers can materially affect revenue if orders slow or are lost.

    Kohdistuu: One customer accounted for 21.6% of quarterly revenue in the latest quarter.

  2. Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Korkea

    Commercial expansion depends on satisfying local medical and screening regulations.

    Kohdistuu: APAC rollout and US clinical/regulatory work were explicitly cited.

  3. Financing and going-concern pressureVaikutus: KorkeaTodennäköisyys: Korkea

    The company is loss-making and relies on external funding and support to continue scaling.

    KohdistuuOngoing lossesDeferred grant incomeCapital market dependence
  4. Supplier concentrationVaikutus: KorkeaTodennäköisyys: Matala

    The company relies on a limited supplier base for direct materials used in cartridges and readers.

    Kohdistuu: Largest suppliers accounted for 29.1% of quarterly purchases.

  5. Nasdaq listing complianceVaikutus: KeskitasoTodennäköisyys: Korkea

    Failure to meet continued listing requirements could impair liquidity and fundraising.

    Kohdistuu: Management disclosed prior risk of delisting for minimum bid price issues.

Kysy Clarifolta: Intelligent Bio Solutions Inc

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition by product type

Cartridges, readers, and accessories are recognized differently depending on shipment and delivery terms.

Vaikutus: Quarterly revenue and gross margin can swing with product mix.

Government support income and R&D tax refunds

These items are material to reported results and depend on qualifying spend and grant timing.

Vaikutus: Can significantly reduce net loss in periods when recognized.

Deferred grant income

Grant proceeds are recorded as a liability and recognized over time as conditions are met.

Vaikutus: Affects current liabilities and future other income.

Foreign currency translation

The company operates internationally and settles transactions in multiple currencies.

Vaikutus: Can create gains or losses in other comprehensive income and earnings.

Going concern and liquidity judgments

Losses, working capital needs, and financing dependence require management estimates.

Vaikutus: Affects disclosure, valuation assumptions, and investor perception.

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Innovative Payment Solutions, Inc.

IPSI · Retail-Catalog & Mail-Order Houses

Rapid Micro Biosystems, Inc

RPID · Laboratory Analytical Instruments

Harvard Bioscience, Inc

HBIO · Laboratory Analytical Instruments

iBio, Inc.

IBIO · Pharmaceutical Preparations

Bio Green Med Solution, Inc.

BGMSP · Wholesale-Durable Goods, NEC

Global Innovative Platforms Inc.

GIPL · Surgical & Medical Instruments & Apparatus

Päivitetty: 24.9.2026

Intelligent Bio Solutions Inc (INBS) liikevaihto, tulos ja tunnusluvut 2026 – Clarifo